Edition:
United States

Acasti Pharma Inc (ACST.O)

ACST.O on Consolidated Issue listed on NASDAQ Capital Market

1.56USD
12 Dec 2017
Change (% chg)

$-0.04 (-2.50%)
Prev Close
$1.60
Open
$1.58
Day's High
$1.58
Day's Low
$1.55
Volume
52,315
Avg. Vol
350,181
52-wk High
$3.36
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​
Wednesday, 22 Nov 2017 08:00am EST 

Nov 22 (Reuters) - Acasti Pharma Inc :Acasti Pharma Inc - ‍clarifies term of proposed strategic partnership with China pharmaceutical company​.Acasti - Under proposed term, Chinese pharmaceutical co to be granted exclusive license to commercialize CaPre in certain Asian countries including China​.  Full Article

Acasti Pharma ‍enters into non-binding agreement with China-based pharma
Monday, 20 Nov 2017 08:00am EST 

Nov 20 (Reuters) - Acasti Pharma Inc :Acasti Pharma Inc - ‍entered into a non-binding term sheet with a China-based pharmaceutical company​.Acasti Pharma - ‍if definitive agreement is reached, signed, term sheet contemplates co would receive an upfront payment of us$8 million upon signing.Acasti Pharma Inc - ‍if definitive agreement is reached & signed, co would also receive potential additional milestone payments in excess of $125 million​.  Full Article

Acasti Pharma says is offering 11.7 mln common shares‍​
Thursday, 16 Nov 2017 05:36pm EST 

Nov 16 (Reuters) - Acasti Pharma Inc :Says it is offering 11.7 million common shares‍​ - SEC Filing.  Full Article

Acasti Pharma reports Q2 loss per share C‍$0.31​
Monday, 13 Nov 2017 05:30pm EST 

Nov 13 (Reuters) - Acasti Pharma Inc :Acasti Pharma reports second quarter FY 2018 financial results.Acasti Pharma Inc qtrly loss per share C‍$0.31​.  Full Article

Acasti Pharma files for offering of up to $17.25 mln of common stock‍​
Friday, 29 Sep 2017 05:48pm EDT 

Sept 29 (Reuters) - Acasti Pharma Inc :Acasti Pharma Inc files for offering of up to $17.25 million of common stock‍​ - sec filing‍​.  Full Article

Acasti Pharma reports Q1 loss per share c$0.19
Monday, 14 Aug 2017 05:30pm EDT 

Aug 14 (Reuters) - Acasti Pharma Inc -:Acasti Pharma reports first quarter fy 2018 financial results.Q1 loss per share c$0.19.  Full Article

Acasti Pharma reports Q4 and FY 2017 financial results
Tuesday, 6 Jun 2017 04:30pm EDT 

June 6 (Reuters) - Acasti Pharma Inc ::Acasti Pharma reports fourth quarter and full-year 2017 financial results.Acasti Pharma Inc - ‍net loss for three-month period ended february 28, 2017 was $0.23 loss per share​.  Full Article

Acasti Pharma says CaPre Phase 3 on track to start in late 2017
Thursday, 30 Mar 2017 08:15am EDT 

Acasti Pharma Inc : Acasti Pharma provides update on capre phase 3 development program . Confirms phase 3 program is on track to start late 2017 .Acasti Pharma - FDA's feedback supports co's plan to conduct two studies instead of one large study, potentially shortening time to NDA submission.  Full Article

Acasti Pharma announces pricing for its public offering of units
Friday, 10 Feb 2017 04:26pm EST 

Acasti Pharma Inc : Acasti Pharma announces pricing for its public offering of units .Acasti Pharma- entered agency agreement with Echelon Wealth Partners as sole bookrunner, lead agent; agent to offer units for proceeds of C$4.5 million-C$8 million.  Full Article

Acasti Pharma Q3 loss C$0.22/shr
Thursday, 12 Jan 2017 05:15pm EST 

Acasti Pharma Inc : Acasti Pharma reports third quarter 2017 financial results . Q3 loss per share C$0.22 . Acasti pharma - Had cash,short-term investments of $5.8 million as of Nov 30, 2016 .Acasti Pharma - if co doesn't raise additional funds, there exists material uncertainty casting substantial doubt about ability to continue as going concern.  Full Article

BRIEF-Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​

* Acasti Pharma Inc - ‍clarifies term of proposed strategic partnership with China pharmaceutical company​